Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Adaptimmune
ClinicalTrials.gov Identifier:
NCT01350401
First received: May 2, 2011
Last updated: December 7, 2016
Last verified: December 2016

May 2, 2011
December 7, 2016
May 2011
March 2016   (final data collection date for primary outcome measure)
NCI CTC V.4 Adverse Events related to study treatment greater than or equal to Grade 3 [ Time Frame: Daily monitoring from Day1-Day 16, weekly thereafter through week 12, monthly thereafter through month 12. ] [ Designated as safety issue: Yes ]
Determine the safety and tolerability of a fixed split-dose of autologous t cells transduced with lentiviral vector encoding an enhanced TCR after non-myeloablative chemotherapy.
Safety and Tolerability of T cell infusions [ Time Frame: Weekly monitoring of AE's from Week 2-Week 12 ] [ Designated as safety issue: Yes ]
To determine the safety and tolerability of a fixed split dose of autologous T cells transduced with lentiviral vector encoding an enhanced TCR after non-myeloablative chemotherapy. Adverse events will be monitored for DLT's as defined by 1) any grade 3 or higher not related to chemotherapy; 2) any grade 2 or higher allergic reaction and 3) andy grade 3 or higher autoimmunity that involves vital organs such as heart, kidneys, brain, eye, liver, colon, and adrenal gland. DLT's are defined as acute (0-10 days post CTX) or delayes (> 10 days after CTX).
Complete list of historical versions of study NCT01350401 on ClinicalTrials.gov Archive Site
  • Tumor Response [ Time Frame: Baseline, every 4 weeks until month 5 and then every other month through month 11 ] [ Designated as safety issue: No ]
    Clinical Activity of TCR gene therapy as assessed by RECIST (version 1.1) criteria and progression-free survival
  • Persistence of modified T cells in the peripheral blood [ Time Frame: Days: 1, 5-9, 12-16, weekly thereafter through week 12, monthly thereafter through month 12, and during LTFU ] [ Designated as safety issue: No ]
    To determine the persistence of modified T cells in the peripheral blood and at tumor sites.
  • T cell function [ Time Frame: Weeks 4 and 8 post T cell infusion ] [ Designated as safety issue: No ]
    To determine the functional properties and phenotype of modified T cells from peripheral blood and tumor sites. T cell function is essential to document the activity (or inactivity) of TCR positive T cells isolated from each patient at certain time points after adoptive transfer.
  • Clinical Activity TCR gene therapy as assessed by RECIST criteria and progression-free survival [ Time Frame: every 4 weeks while on study up 12 week ] [ Designated as safety issue: No ]
    To determine the clinical activity TCR gene therapy as assessed by RECIST criteria and progression-free survival. Tumor measurements will be repeated q4weeks using RECIST criteria. Progression free survival will be calculated.
  • Persistence of modified T cells in the peripheral blood [ Time Frame: Days: 1, 5-9, 12-6, then weekly for 10 weeks ] [ Designated as safety issue: No ]
    To determine the persistence of modified T cells in the peripheral blood and at tumor sites.
  • T cell function [ Time Frame: Weeks 4 and 8 post T cell infusion ] [ Designated as safety issue: No ]
    To determine the functional properties and phenotype of modified T cells from peripheral blood and tumor sites. T cell function is essential to document the activity (or inactivity) of TCR positive T cells isolated from each patient at certain time points after adoptive transfer. We hypothesize that functional TCR positive T cells as assessed by our ex vivo analysis will be associated with clinical response and improved outcomes. In contrast, anergic T cells will be associated with disease progression.
Not Provided
Not Provided
 
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells Against Cancer-testis Antigens in Metastatic Melanoma
The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
Purpose of this study is to evaluate the safety and tolerability of autologous genetically modified T cells. Genetic material is transferred into the subject's previously harvested autologous T cells to redirect them to target melanoma cells rather than their usual target. Study subjects must have histologically or cytologically melanoma stage 3/4 and their tumor must express HLA Class 1 allele HLA-A*0201 for NY-ESO-1/LAGE. Subjects must also have measureable disease on study entry, as defined by at least one lesion that can be measured in at least one dimension >= 10mm with spiral CT scan.
Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma
Biological: NY-ESO-1
Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells
Experimental: NY-ESO-1
Subject's tumor must express cancer testis antigen NYESO-1 and be HLA-A*02 positive
Intervention: Biological: NY-ESO-1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4
May 2031
March 2016   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Patients must have histologically or cytologically confirmed melanoma stage III/IV, unresectable
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with spiral CT scan
  • One prior cytotoxic therapy for the treatment of metastatic disease is allowed. Unlimited regimens using biological agents (vaccines), immunotherapy, or targeted agents is permitted. For example, BRAF inhibitors and ipilimumab are permitted. Patients must have fully recovered from the acute toxicities related to any prior therapy. Prior therapy must be completed ≥28 days before the first dose of cyclophosphamide.
  • Age ≥18
  • Life expectancy of greater than 3 months
  • ECOG performance status ≤ 1

Patients must have normal organ and marrow function as defined below:

  • Leukocytes ≥ 3,000/mcL
  • Absolute Neutrophil Count (ANC) ≥ 1,500/mcL
  • Platelets ≥ 100,000/mcL
  • Total bilirubin within normal institutional limits
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal
  • Creatinine ≤ 2.0 mg/dl Or Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • The patient must express HLA class I allele HLA-A*0201 for NY-ESO-1/LAGE.
  • Patient must have proven positive tumor sample for NY-ESO-1 as determined by an H score for immunohistochemistry staining. Positive expression is defined as an H score ≥ 100 where the H score = [2 x (% cells 2+) + 3 x (% cells 3+)].

NOTE: The percentages of negative or weakly stained nuclei (i.e. 1+) are not to be included in the calculation of the H score.

  • Female subjects of childbearing potential must have a negative pregnancy test and both male and female (of childbearing potential) subjects must agree to use reliable methods of contraception during the study.
  • Ability of the patient (or legally authorized representative if applicable) to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Patients who have had 2 or more regimens containing cytotoxic chemotherapy for metastatic melanoma.
  • Patients may not be receiving any other investigational agents.
  • Patients with active brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.
  • Active infection
  • Prior malignancy (except non-melanoma skin cancer) within 3 years.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. All patients will undergo a cardiac stress test for evaluation of cardiac function.
  • Pregnant or nursing females
  • Active infection with HIV, HBV or HCV as defined below, due to the immunosuppressive effects of cyclophosphamide used and the unknown risks associated with viral replication.
  • Positive serology for HIV
  • Active Hepatitis B infection as determined by test for hepatitis B surface antigen.
  • Active Hepatitis C. Patients will be screened for HCV antibody. If the HCV antibody is positive, a screening HCV RNA by any RT-PCR or bDNA assay must be performed at screening by a local laboratory with a CLIA certification or its equivalent. Eligibility will be determined based on a negative screening value. The test is not required if documentation of a negative result of a HCV RNA test performed within 60 days prior to screening is provided.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01350401
ADP 01611
Yes
Not Provided
Not Provided
Adaptimmune
Adaptimmune
Not Provided
Principal Investigator: Gerald P Linette, MD, PhD Washington University School of Medicine
Principal Investigator: Harriet Kluger, MD Yale New Haven Hospital
Adaptimmune
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP